ETON - CIK 0001710340
Eton Pharmaceuticals, Inc. trades as ETON. In its fiscal 2025 annual report the company posted revenue of $79.95M, up 104.9% from the prior year and net income of -$4.60M. This page tracks Eton Pharmaceuticals, Inc. through 371 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years Eton Pharmaceuticals, Inc.'s revenue grew from $959.00K to $79.95M, a compound annual growth rate of 109.0%. Net profit margin expanded from -1910.3% to -5.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| Insider sale notice | 144 | 2026-05-22 |
| Major company event | 8-K | 2026-05-19 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Major company event | 8-K | 2026-05-01 |
| Major company event | 8-K | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-24 |
The largest companies sharing Eton Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Eton Pharmaceuticals, Inc. reported revenue of $79.95M for fiscal year 2025, an increase of 104.9% year over year.
In its latest fiscal year Eton Pharmaceuticals, Inc. reported a net loss of $4.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.